# OnCo record nct06082102 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06082102/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06082102", "NCT06082102" ;
  schema:name "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma"@en ;
  schema:description "A phase 3 trial of Orelabrutinib, Rituximab and Lenalidomide in non-Hodgkin lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06082102/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06082102> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-12-19" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/orelabrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/innocare/> .